论文部分内容阅读
目的:观察稳心颗粒治疗室性期前收缩的疗效及其安全性。方法:80 例患者在常规治疗的基础上,停用抗心律失常药物至少5个半衰期后,给予稳心颗粒治疗,每次 1 包(9 g),tid,温开水冲服,4 周为 1 个疗程。结果:服用稳心颗粒4周后,86.25%患者症状明显改善,实验室检查及 HR、PR间期、QRS时限、QT间期与用药前比较差异无统计学意义(P>0.05)。对全部室性期前收缩患者显效率 58.75%,总有效率为 86.25%,与治疗前比较差异有统计学意义(P<0.01)。其中30例功能性室性期前收缩患者显效率 70.0%,总有效率 93.3% 。结论:稳心颗粒对于治疗室性期前收缩,尤其是功能性室性期前收缩疗效显著,且该无明显不良反应。
Objective: To observe the efficacy and safety of Wenxin Granule in the treatment of premature ventricular contractions. Methods: Eighty patients were treated with Wenxin granule after stopping the anti-arrhythmic drugs for at least 5 half-lives on the basis of routine treatment. Each capsule (9 g), tid, Course of treatment. Results: The symptom of 86.25% patients was significantly improved after taking Wenxin Granule for 4 weeks. There was no significant difference in the laboratory examination and HR, PR interval, QRS duration, QT interval and before treatment (P> 0.05). The effective rate was 58.75% in all patients with premature ventricular contractions, the total effective rate was 86.25%, with statistical significance (P <0.01). Among them, 30 cases of functional ventricular premature contractions markedly effective rate was 70.0%, the total effective rate 93.3%. Conclusion: Wenxin Granule has a significant effect on the treatment of premature ventricular contraction, especially premature ventricular contraction, and no obvious adverse reactions.